Article Information
History
- September 18, 2021.
Article Versions
- Version 1 (June 14, 2021 - 17:18).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Meagan P. O’Brien, M.D.1,*,
- Eduardo Forleo-Neto, M.D.1,
- Neena Sarkar, Ph.D.1,
- Flonza Isa, M.D.1,
- Peijie Hou, Ph.D.1,
- Kuo-Chen Chan, Ph.D.1,
- Bret J. Musser, Ph.D.1,
- Katharine J. Bar, M.D.2,
- Ruanne V. Barnabas, M.D.3,
- Dan H. Barouch, M.D., Ph.D.4,
- Myron S. Cohen, M.D.5,
- Christopher B. Hurt, M.D.5,
- Dale R. Burwen, M.D., M.P.H.6,
- Mary A. Marovich, M.D.6,
- Elizabeth R. Brown, Sc.D.7,
- Ingeborg Heirman, Ph.D.1,
- John D. Davis, Ph.D.1,
- Kenneth C. Turner, Ph.D.1,
- Divya Ramesh, Ph.D.1,
- Adnan Mahmood, M.D.1,
- Andrea T. Hooper, Ph.D.1,
- Jennifer D. Hamilton, Ph.D.1,
- Yunji Kim, Pharm.D.1,
- Lisa A. Purcell, Ph.D.1,
- Alina Baum, Ph.D.1,
- Christos A. Kyratsous, Ph.D.1,
- James Krainson, M.D., C.P.I., R.P.S.G.T.8,
- Richard Perez-Perez, M.D.9,
- Rizwana Mohseni, D.O.10,
- Bari Kowal, M.S.1,
- A. Thomas DiCioccio, Ph.D.1,
- Neil Stahl, Ph.D.1,
- Leah Lipsich, Ph.D.1,
- Ned Braunstein, M.D.1,
- Gary Herman, M.D.1,
- George D. Yancopoulos, M.D., Ph.D.1,
- David M. Weinreich, M.D.1,
- for the COVID-19 Phase 3 Prevention Trial Team
- 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
- 2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA
- 3Department of Global Health, University of Washington, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- 4Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
- 5Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA
- 6National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA
- 7Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA
- 8Clinical Trials of Florida, LLC, Miami, FL, USA
- 9Medical Research of Westchester, Miami, FL, USA
- 10Catalina Research Institute, LLC, Montclair, CA, USA
- ↵*Corresponding author; email: meagan.obrien{at}regeneron.com
Posted September 18, 2021.
Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
